Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC0650-0013
- Development stage
- Phase 1
- Lead developer
- Novo Nordisk
- Modality
- Peptides
- Administration
- Subcutaneous, Intravenous
01
Overview
NNC0650-0013 is an investigational drug being developed by Novo Nordisk for the treatment of type 2 diabetes mellitus. It is currently in Phase I clinical development, with studies evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers following single ascending doses administered either subcutaneously or intravenously. As an early-stage compound, its specific molecular target and mechanism of action have not been publicly disclosed by the developer, though its development aligns with Novo Nordisk's focus on metabolic diseases and injectable therapies.
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on NNC0650-0013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC0650-0013.